Hims & Hers Health enters its June 11 print with a positioning picture that has barely shifted since last week — short sellers remain deeply entrenched, options traders have pulled back from their most aggressive call positioning, and the stock has added another leg higher.
The options signal has normalised since the extreme bullishness flagged in last week's note. The put/call ratio has edged back up to 0.59, essentially in line with its 20-day average of 0.59 — a z-score near zero confirms there is no directional lean in the options market at this point. That is a meaningful change from the 0.52 PCR reading documented on June 3, which was the most call-heavy positioning of the past year. The retreat toward neutral suggests options traders have already expressed their upside view through the stock's 5% gain on the week to $28.98, and are no longer piling on ahead of the number.
The short book is unmoved, and the borrow market remains as tight as it gets. Short interest is 28.5% of the free float — down roughly 11.5% over the past month in share terms, but still one of the most heavily shorted names in the sector, with an ORTEX short score of 68.6. Availability has held at zero percent for weeks, meaning every share in the lending pool is currently out on loan, and cost to borrow has risen 20% over the past week to 1.23%. That combination — high short interest, zero availability, rising borrow cost — describes a borrow market under genuine strain. Shorts have not covered meaningfully into the recent rally, which means the short book is sitting on losses relative to early May levels when SI was running above 70 million shares.
The bull and bear cases reflect a company at a genuine crossroads. Bulls point to a Novo Nordisk partnership, a long-term revenue target that commands attention, and an ORTEX factor score showing 90th-percentile forward EPS growth expectations. Bears counter with slowing near-term momentum — EPS surprise ranks in just the 3rd percentile — declining margins, and the regulatory overhang on compounding operations in the GLP-1 space. The analyst community is broadly on the fence: BofA has trimmed its target three times since mid-May, most recently to $25, while JPMorgan holds an Overweight at $33 and Needham maintains Buy with a $35 target. The mean target of $26.61 now sits fractionally below the current price of $28.98, leaving the stock technically ahead of where the Street expected it at this point.
The May 11 print — an 11.5% drop on the day and a 21% slide over the following five sessions — set the bar for what a disappointing number does to HIMS. Thursday's report is therefore less a test of whether the company is growing and more a question of whether the GLP-1 revenue stream is durable enough, at margins robust enough, to justify a stock that has outrun its consensus price target into the announcement.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
